The global biopsy devices market, which was valued at USD 2.25 billion in 2023, is projected to expand significantly, growing at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2030. Several key factors are contributing to the market's growth, including the rising global prevalence of cancer, an increasing emphasis on minimally invasive surgeries, the presence of untapped opportunities in emerging economies (especially in the Asia Pacific region), and improvements in healthcare infrastructure worldwide.

One of the primary drivers behind the growth of the biopsy devices market is the increasing global burden of cancer. According to the Union for International Cancer Control (UICC), it is projected that the number of new cancer cases will rise to more than 35 million by 2050, reflecting a significant increase of approximately 77% from the estimated 20 million cases in 2022. This sharp rise in cancer cases will likely spur an increased demand for diagnostic tools and procedures, including biopsy devices, as these are essential for accurate cancer diagnosis and staging. Biopsy devices are used to collect tissue samples for examination, enabling healthcare professionals to determine whether cancer is present and to identify the type and extent of the disease. As the number of cancer diagnoses increases, the need for advanced biopsy technologies will grow correspondingly.

Gather more insights about the market drivers, restrains and growth of the Biopsy Devices Market

Shift Toward Minimally Invasive Procedures

Another key factor driving market growth is the growing preference for minimally invasive surgical procedures. Minimally invasive surgeries, which involve smaller incisions and generally less trauma to the body, have gained immense popularity in recent years due to the multiple benefits they offer, including reduced recovery times, fewer complications, less pain, and shorter hospital stays. This trend has had a direct impact on the biopsy devices market, as these procedures are often used in conjunction with advanced biopsy technologies.

The demand for minimally invasive biopsy techniques is not only increasing because of the benefits to patients but also because of the continuous technological advancements that make such procedures safer and more effective. For instance, in July 2022, a new biopsy technology was introduced at NewYork-Presbyterian/Columbia, which provides a less invasive, safer, and more efficient option for performing lung biopsies. This innovation highlights the growing efforts to develop more patient-friendly biopsy methods while maintaining or improving diagnostic accuracy.

Government and Healthcare Investment in Cancer Research

As the prevalence of cancer continues to rise, governments and healthcare organizations are ramping up their efforts to address this growing health crisis. A significant part of these efforts includes increasing funding for cancer research, which plays a crucial role in the development of more effective diagnostic tools, including biopsy devices. For example, in 2022, the U.S. National Cancer Institute (NCI) allocated USD 6.8 billion in funding for cancer research, marking a 5.7% increase from the previous fiscal year. These investments not only support the development of new biopsy technologies but also facilitate research into the most effective ways to diagnose and treat various types of cancer.

Governments and health bodies across the globe are also focusing on improving early detection rates for cancer, which is crucial for enhancing survival outcomes. Early detection of cancer typically leads to more effective treatment options and better prognosis. This focus on early detection has led to an increased emphasis on regular diagnostic screenings, which often involve biopsy procedures. In this context, a range of healthcare institutions has initiated public awareness campaigns to encourage regular screenings and educate people on the importance of early cancer detection. One notable example is the "Right to Know" campaign launched by the Centers for Disease Control and Prevention (CDC). This initiative aims to raise awareness about the importance of breast cancer screening, particularly among women with disabilities, who are often underserved in terms of healthcare access.

Order a free sample PDF of the Biopsy Devices Market Intelligence Study, published by Grand View Research.